XOMA Corporation is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.
The XMet platform consists of separate classes of Selective Insulin Receptor Modulators (SIRMs), XMetD and XMetA, which could have a major impact on the treatment of metabolic disorders.
XOMA is also developing gevokizumab, an interleukin-1β (IL-1β) modulating antibody. XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with non-infectious uveitis. XOMA is conducting a Phase 3 program in pyoderma gangrenosum, a rare ulcerative skin disease, and is implementing blinded futility analyses into the Phase 3 clinical program to allow informed go/no go decisions. Servier is also studying gevokizumab in several Phase 2 and proof-of-concept (POC) studies.
In addition, the Company is exploring the sale of its manufacturing facilities and its biodefense programs. XOMA 3AB, an antibody candidate in preclinical development to neutralize the botulinum toxin, among the most deadly bioterrorism threats, is under development through funding provided by the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
XOMA is located in Berkeley, California.
Aug 11, 2015 at 2:30 PM ET
Wedbush PacGrow Healthcare Conference
Aug 6, 2015 at 4:30 PM ET
Second Quarter 2015 Financial Results Conference Call